Strategies to Improve Treatment - Remission Induction Therapy

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Researchers are currently investigating new treatments involving remission induction therapy for acute myeloid leukemia (AML). Participation in trials of these treatments may lead to improved therapies. If you wish to participate in a clinical trial, please talk to your doctor about the potential benefits and side effects of the treatment.

New drug development - All new drugs for the treatment of patients with AML are tested first in patients with relapsed or refractory disease. When they are found to be effective, they are then evaluated in remission induction regimens.

  • Mylotarg® (gemtuzumab ozogamicin) - Mylotarg is a targeted chemotherapy. It consists of a monoclonal antibody attached to calicheamicin, an antibiotic that kills cancer cells. Monoclonal antibodies are proteins that can be produced in a laboratory. They have the ability to attach themselves to certain types of cells.

    Gemtuzumab ozogamicin attaches specifically to leukemia cells. Once the monoclonal antibody binds to the cancer cells, calicheamicin is absorbed by the cells and kills them. Because gemtuzumab ozogamicin mainly targets cancer cells, healthy cells are not killed by it. This is unlike chemotherapy or radiation. Both of these attack cancer cells and healthy cells. This causes considerable side effects.

    Several research groups are now conducting clinical trials evaluating gemtuzumab ozogamicin plus intensive chemotherapy to treat AML. A recent study by the Medical Research Council in England showed that adding gemtuzumab ozogamicin to chemotherapy during induction and in the third chemotherapy treatment improves disease-free survival and decreases the relapse rate in patients with AML.
  • New drugs - Many new drugs are being tested alone or in combination to treat AML, including clofarabine, DacogenTM (decitabine), cloretazine, and vaccines. Ask your doctor about his or her opinion regarding these new trials.
This content was last modified on August 11, 2007 .
Latest Cancer News
ACS Guidelines for Breast Screening with MRI May Be Excluding Some High-risk Women

January 6, 2009 — The American Cancer Society (ACS) has developed a set of guidelines to recommend which high-risk women need to undergo screening with breast magnetic resonance imaging (MRI); however, these guidelines may unwittingly exclude some women who are at a high risk of carrying the BRCA mutation yet still don’t meet the limitations set by the ACS. The results of this study were published in the journal Cancer.

Colonoscopy Fails to Identify Many Colorectal Cancers

January 6, 2009 — Colonoscopy, a standard screening method for colorectal cancer, misses the majority of cancers on the right side of the colon and about one-third of cancers on the left side of the colon, according to the results of a study published in the Annals of Internal Medicine. The researchers estimated that the screening method may reduce colorectal cancer mortality by 60-70%, rather than 90% as previously estimated.

High-dose Faslodex® Improves Time to Progression Compared with Arimidex® as Initial Therapy in Advanced Breast Cancer

January 6, 2009 — Researchers affiliated with an international trial have reported that high-dose Faslodex® (fulvestrant) significantly improves time to cancer progression compared with Arimidex® (anastrozole) as initial therapy for hormone-positive, advanced breast cancer. These results were recently presented at the 2008 annual San Antonio Breast Cancer Symposium December 10-14, 2008.

Select news items provided by Reuters Health